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Abstract:
SRTR program reports provide detailed information on transplant center performance relative to
risk-adjusted expected values. Designed to improve outcomes, the behavioral implications of
these reports may generate a longer wait time for transplant. UNOS data for 28,839 deceased
donor kidney transplants performed during 6/2007- 6/2010 and 79,725 registered patients
waiting for a kidney transplant during this time period were merged with SRTR program report
data; Patient-specific and transplant center controls were created. An indicator variable was
constructed for whether or not a transplant center did not meet the Centers for Medicare and
Medicaid Services (CMS) Conditions of Participation (CoP) during a patient’s waiting period for
a transplant. A censored Cox-proportional hazard model was utilized to investigate the impact of
CMS CoP on the length of time until transplant. Data analysis reveals that a transplant center’s
failure to meet either the 1-year graft or patient survival rates, according to CMS criteria, is
associated with the expected waiting time until transplantation. Further the results suggest that

centers may elect to transplant healthier patients and patients for whom they would receive a
risk compensation in the SRTR model.

INTRODUCTION
End Stage Renal Disease (ESRD) is a significant health burden in the United States,
with more than 300,000 people being dialysis–dependent (1) The rapid expansion of the kidney
transplant waiting list, particularly of older and higher risk patients, has heightened the
awareness of the transplant and medical community to the importance of optimizing the use of
scarce organs. However, the transplant surgeon’s decision to accept and utilize an organ is
made in the presence of considerable regulatory (2-4) and patient health-related risks (5, 6).
Transplant centers are required to report patient and graft outcomes. The Scientific
Registry of Transplant Recipients (SRTR) reports risk adjusted outcome data for each
transplant center using a 2½ year rolling cohort that is updated and published every 6-months.
When outcomes deviate from an expected value, a peer review process is initiated with the
intent of stimulating improvement and best practices in underperforming transplant centers.
CMS assumed an increased role in transplantation on June 28, 2007 and as a result certifies
transplant centers for participation in the Medicare program using outcome requirements
outlined in the CoP (7). Failure to meet performance standards may result in a center entering
a Systems Improvement Agreement and potential loss of funding by CMS.
CMS currently uses a three-pronged trigger system to determine when a transplant
center does not meet performance standards under the CoP. In terms of graft survival rates, a
CMS trigger results when all three of the following triggers are met: (1) (observed graft failures –
expected graft failures) > 3; (2) (observed graft failure/expected graft failure) > 1.5; and (3)
differences are statistically significant at the 5% level using a one-sided t-test. Failure to meet
only one or two of these triggers does not cause a center to not meet the CoP, all three triggers
must be simultaneously met. Each of these statistics is reported in the SRTR transplant center

reports as well as a two-tailed test of statistical significance. A 10% signifigance level, as
reported in the SRTR reports, is equivalent to the 5% level one-tailed test used by CMS for the
CoP. Furthermore, all of the expected outcomes calculated are risk-adjusted based on both
recipient and donor characteristics (2).
While quality assurance has led to significant improvements in the care of transplant
patients (8, 9)there are potential negative implications of such efforts (10). In particular, the
CMS CoP may induce more risk-averse and/or loss-averse preferences (11). A byproduct of the
regulation then may be an increased waiting time for patients as the behavioral response of
surgeons is to be more selective and therefore may cause transplant centers to reduce the
number of organs accepted for transplant. However, it is worth noting that these behavioral
responses may be consistent with the objective of the CMS CoP. The purpose of this study is to
not to investigate the efficacy of the CMS CoP but to investigate its impact on deceased donor
waiting times for kidney transplantation in the United States. We leave the question of whether
or not the CMS CoP results are welfare enhancing for future research. Our primary hypothesis
is that waiting times will increase at a transplant center after it learns that it does not meet its
CMS CoP.
METHODS:
Data acquisition:
UNOS data for 28,839 deceased donor kidney transplants performed during 6/20076/2010 and 79,725 registered patients waiting for a kidney transplant during this time period
were merged with SRTR program report data. 1-year graft and patient survival rates expressed
as both the total number of transplants and by deceased donors only were analyzed. 187
transplant centers performing an average of at least one transplant per month during 1/20046/2010 were included. This larger time window for center selection was utilized because it
captured all transplant patients included in the 2 ½ year rolling cohort reported in the June 2007
SRTR center reports. Transplant center averages, used to determine their inclusion in our

study, were determined by adding up the total number of transplants conducted between 1/2004
and 6/2010, as reported in the UNOS data set, and then dividing by the total number of months.
Our data set contains approximately 91% of all the transplants conducted and 88% of patients
waiting for a deceased donor kidney transplant during this time period.
For each deceased-donor kidney transplant performed the waiting time was estimated
using the patient’s transplant date and their initial waiting list date. For those patients awaiting
transplant the waiting time was similarly calculated but truncated at 06/30/2010, the end date of
analysis. All patients currently waiting are censored and controlled for in the empirical model.
Cummulative distribution and censored Cox-proportional hazard model:
The cummulative distribution function of patient waiting times when their center meets
the CMS CoP before transplantation and when their center does not meet the CMS CoP at least
once during their wait time are shown in Figure 2.
To investigate the impact that the CMS CoP has on patient waiting times a censored
Cox-proportional hazard model was estimated. The hazard function, i.e. the instaneous
probability that a patient receives a kidney at

t is specified as,

h(t) = h0 (t)e X ' b
where

(1)

t represents current time period, X is the matrix of exogenous variables that affect the

length of time until transplant, exp( b ) is the estimated vector of hazard ratios of the exogenous
variables and h0 (t) is the baseline hazard rate.
Two alternative specifications of X ' b were estimated. In both specifications, the
common set of covariates include the following variables: transplant center fixed effects and
patient specific factors (i.e., gender, ethnicity, medical insurance, working status, functional
status at listing, diabetes, vascular disease, angina, hypertension, body mass index (BMI), age
and panel reactive antibody (PRA)). In the first specification an indicator variable is added,
defined as C , that takes a value of one if a patient’s transplant center does not meet the CMS

CoP at least once during their waiting time. The second specification interacts the variable C
with a subset of patient-specific factors that may be used to differentiate between a high and low
risk patient including a patient’s functional status at listing, diabetes status, the presence of
vascular disease, hypertension, BMI, age and PRA. Given the importance of a patient’s PRA
level in transplantation we have elected to define PRA two different ways: (1) initial PRA at
listing and (2) maximum observed PRA level recorded in the UNOS data set. The initial PRA is
recorded at the time of listing, however the PRA values are updated during the course of a
patient’s wait time and at the time of transplantation. Therefore, by defining the PRA levels both
ways we can investigate the sensitivity of our results to alternative PRA specifications. However,
we do treat both measures of the PRA as time-invariant variables in Equation (1) because we
do not know the precise PRA for all days that a patient is waiting for a transplant (e.g., we do
not have real-time PRA data for the patient). The patient’s functional status is further partitioned
into four types: (1) performs activities of daily living with no assistance, (2) performs activities of
daily living with some assistance, (3) performs activities of daily living with total assistance, and
(4) unknown functional status.1 Four different specifications of

C

are used in the model: (1) 1-

year total graft survival; (2) 1-year deceased donor graft survival; (3) 1-year total patient
survival; and (4) 1-year deceased donor patient survival.
RESULTS:
The percentage of transplant centers that do not meet CMS CoP criteria
Nine SRTR report dates were analyzed with data from the period 6/2007-6/2010. The
results are displayed in Figure 1, and categorized by the respective triggers used by CMS for
the CoP. On average, 9.73% of transplant centers did not meet the 1-year CMS CoP for total
1

Functional status 1 aggregates the following UNOS codes:1, 2090, 2080, 4100, 4090 and 4080.
Functional status 2 aggregates the following UNOS codes: 2, 2060, 2070, 2050, 2040, 4070, 4060, 4050
and 4040. Functional status aggregates the following UNOS codes: 3, 2040, 2030, 2020, 2010, 4030,
4020 and 4010.

graft survival, 8.21% for deceased donor graft survival, 7.83% for total patient survival and
6.23% for deceased donor patient survival.
The percentage of transplants occuring at centers that do not meet CMS CoP criteria
Of the 28,839 transplants analyzed, 9.36% [2,698] occurred at transplant centers that did not
meet the CMS CoP standards for 1-year total graft survival at least once during the waiting time.
The percentages of transplants conducted at centers failing to meet other (stated) standards
were: 9.54% [2,751] (1-year deceased donor graft survival), 11.28% [3,253] (1-year total patient
survival), and 8.68% [2,502] (1-year deceased donor patient survival) respectively.
The percentage of registered patients on the waitlist at a center that does not meet CMS
CoP criteria
Of the 79,725 registered patients waiting for a kidney transplant, 8.96% [7,147] were waiting for
a transplant at a center that had not met the CMS CoP standard for 1-year total graft survival at
least once during their waiting time. The percentages of registered patients waiting for a kidney
transplant at centers failing to meet other (stated) standards were: 8.93% [7,119] (1-year
deceased donor graft survival, 11.10% [8,857] (1-year total patient survival) and 9.40% [7,497]
(1-year deceased donor patient survival) respectively.
Univariate analysis of wait times when a center does not meet the CMS CoP
Table 1 shows the descriptive statistics for the data set partitioned by the four
specifications of

C

as well as by those patients who received transplants and those who did

not. For all of the four CMS CoP criteria and across the two partitions of the data set, those who
received a transplant and those who were still waiting (treating each unique patient as an
independent observation), a two-tailed, two-sample t-test with unequal variances indicate that a
patient’s waiting time is longer when a center does not meet one of the CoP relative to when
they do (all p-values less than 0.01).
A limitation of this univariate analysis is that it treats each observation as an independent
observation. Given that observations within a transplant center may not be independent, we

also conducted a series of two-sample t-tests at the transplant center level. For each of the four
CMS CoP criteria and two partitions of the data set (transplanted and waiting patients) we
determined the unique centers within each partition and then averaged the waiting times at the
transplant center level. Using this transplant center level data set all of our two-tailed, twosample t-tests with unequal variances indicated that a patient’s waiting time is longer when a
center does not meet one of the CoP relative to when they do (all p-values less than 0.05).
Waiting time increases when a center does not meet the CMS CoP
Figure 2 shows the cummulative distributions of waiting time for transplant for patients
whose centers did not meet the CMS CoP at least once during their waiting time period
categorized by graft and patient type. These data strongly suggest that a patient’s waiting time
increases when a center does not meet the CMS CoP. In all of the panels (analyzed by graft
and patient survival as well as total transplants and deceased donors only) the cummulative
distribution for centers that did not meet the CMS CoP at least once lies within those that met
the CMS CoP the entire time period.
The hazard rates for the CMS CoP criteria using the first specification are reported in
Table 2 and for the second specification in Table 3. The hazard ratios reported in Table 2 vary
from 0.34181 (1-year deceased donor graft survival and maximum observed PRA level) to
0.43433 (1-year deceased donor patient survival and initial PRA level) and are statistically
significant at the 95th percentile. The coefficients indicate that the instantaneous probability of
receiving a transplant conditional on having not received a transplant by that time period, a
patient’s hazard rate, decreases by nearly 64% when a patient’s transplant center has not met
the CMS CoP at least once for 1-year total patient graft survival, by nearly 66% for 1-year
deceased donor graft survival, over 62% for 1-year total patient survival and over 56% for 1year deceased donor patient survival. These hazard ratios are also robust to our use of either
the initial PRA level or the maximum observed PRA level for each patient (PRA variables take a
value of one if the PRA level is greater than or equal to 80 and zero otherwise). A graphical

analaysis of our empirical results, using the maximum observed PRA level, are illustrated in
Figure 3.
Impact at patient level on 1-year total patient and deceased donor graft survival
The results in Table 3 illustrate that impacts on waiting time are not homogenous across
patients and depend on which of the CMS CoP criteria are not being met by the transplant
center. The results for the 1-year total patient graft survival model illustrate that the hazard
function increases for patients who have hypertension by approximately 8% and for those who
have previously received a transplant by between 20% and 24%, depending on which PRA data
are being used in the model. The hazard function decreases by approximately 14% for those
with a functional status of two and and a little over 2% and approximately 0.07% per a unit
increase in a patient’s BMI and age respectively. Lastly, the hazard function decreases by over
12% when the patient’s maximum observed PRA level exceeds 80.
When a transplant center has not met the 1-year deceased donor graft survival CoP at
least once during a patient’s waiting time the hazard function increases for patients with PVD
and hypertension by approximately 25% (26% using maximum observed PRA) and 18%
respectively. The hazard function decreases by nearly 22% when a patient has a functional
status of two and we observe similar reductions to those observed when a center does not meet
the 1-year total transplant graft survival measures for a patient’s BMI, age and maximum PRA
levels.
Impact at patient level on 1-year total patient and deceased donor patient survival
The 1-year total patient and deceased donor survival models generate very similar
results for BMI, age and PRA as those observed in the graft survival models, however the
negative impact of PRA (maximum observed PRA >=80) on the hazard function is slighlty
larger. Additionally, when a transplant center has not met the 1-year total patient survival CMS
CoP criteria at least once during their waiting time the hazard function increases for patients
with diabetes by approximately 12%. This increase reduces to approximately 10% when we

focus on the 1-year deceased donor patient survival. The hazard function for those patients with
a functional status of two falls by nearly 22% and slightly over 20% for the 1-year total patient
survival and 1-year deceased donor patient survival respectively. Lastly, the observed increase
in the hazard function for PVD and hypertension, with the exception of hypertension in the 1year total patient survival model when we use maximum observed PRA (signficant at the 90%
level), in the graft survival models are not observed in the patient survival models.
DISCUSSION:
Transplant centers frequently maintain large waiting lists of patients waiting to receive a
deceased donor transplant. When an organ is accepted or rejected for an individual on the
waiting list, it affects not only that individual, but also those individuals who remain on (or get
into) the waiting list. This decision is made in the presence of data that suggest there is a quality
of life and life expectancy benefit of renal transplant as compared to dialysis (12-14)as well as
the need to maintain excellent recipient and graft survival as monitored by considerable
regulatory oversight. The latter factor may influence transplant centers to be more selective
with the transplants they conduct (15, 16) which may generate longer waiting times. Therefore,
it is important to investigate how these regulations impact not only the transplant centers, but
also the patients who are awaiting transplantation.
While many investigators have focused on the transplant center, this innovative
approach examines outcomes at the patient level and may have the potential to inform the
transplant community on what affects the decisions to accept organs and what impacts the
decisions may have on our patients. This research complements the recent work of Schnier et
al. and Schold et al(11, 17). Schnier et al. highlight the behavioral responses of physicians at
the patient level while Schold et al. discuss the effects at a center level, more specifically the
volume of transplants at a center that may result from the CMS CoP. The finding that failure of a
center to meet the CMS CoP during a patient’s waiting period for transplantation increases their
waiting time is consistent with the findings of Schold et al, (17) and further highlights a potential

mechanism generating this center-level effect; physicians may become more risk averse when
their center does not meet the CMS CoP. Risk aversion would manifest itself as the selection of
healthier patients for transplantation, and/or higher quality donor organs, in order to better
ensure that their transplant center meets the CMS CoP. This may in fact be a desirable
outcome in terms of improved outcomes at the center, but it comes at a cost of a reduced
transplantation rate and increased waiting times. This further illustrates the benefits of focusing
on patient-level decisions in the broader transplant community.
Interestingly, the regulatory impact is not homogeneous across the waiting list population
or the different CoP measures. There are two general consistencies across all four models
estimated. First, patients with a higher BMI, age or a maximum observed PRA greater than 80
will have a longer waiting time when any of the four CoPs are not met. These results confirm the
suggestion that providers may limit access of perceived high risk patients to transplantation (4).
Our second consistency is that patients with a functional status of two will have a longer waiting
time than those patients with a functional status of one or three. This result suggests that
physicians are maintaining their normal flow of transplants for those patients that are either at
the upper (i.e., no assistance patients) or lower end (i.e., total assistance patients) of the health
spectrum, but are electing to not conduct transplants as much for those in the middle health
status class.
Interestingly, a number of the models demonstrate shorter waiting times for patients
whose risk factors are compensated for in the CMS model (i.e., diabetes, hypertension, PVD,
and previous transplant). One interpretation is that physicians are aware of the risk adjustment
and are therefore not as concerned with the impact these patients may have on outcomes.
Another is that phyicians are aware of the risks of these high risk patient populations remaining
on dialysis. And lastly, both factors may be influencing the decision.
Our analysis suggests that regulatory oversight may have an impact on transplant
centers, potentially resulting in fewer transplants and longer waiting times. The question is

whether fewer transplants and longer waiting times is a positive or a negative outcome.
Examining the findings with a negative lens would yield an interpretation that increased
selectivity in the acceptance of organs for transplant may lead to longer waiting times, decline in
health status of waitlist candidates, fewer transplants, longer cold ischemia times, higher organ
discard rates, and a potential disincentive to perform innovative research protocols (11).
Alternatively, these data may demonstrate that centers are acutely aware of performance and
outcomes measures and are becoming appropriately selective, thus serving their patient
population better. Perhaps centers were selecting candidates that were not suitable candidates
or accepting organs that were of lesser quality with the intention of transplanting more patients
and decreasing the waiting times, or both. It is clear that a better understanding of the impact
longer wait times have on the patients on the waiting list needs to be balanced with the positive
aspect of reviewing best practices and improving outcomes (i.e., graft and patient survival).
These results underscore the need for additional research on the individual decision-making of
transplant physicians under a wide range of conditions.
A limitation of our model is the use of large retrospective databases that include
subjective data (i.e, functional status) that may compromise the validity of our results depending
on consistency of data reporting and capture. Additionally, although our findings indicate that a
patient’s waiting time increases if their center did not meet the CMS CoP during the course of
their waiting time, they do not address anticipatory actions taken by a transplant center to
prevent not meeting the CMS CoP, nor do they illustrate whether the longer waiting times result
in either worse or better outcomes for the transplant community.
Transplant centers continually monitor their performance outside of the six-month
intervals used by SRTR. Presumably centers that anticipate themselves not meeting the CMS
CoP may alter their behavior without ever being triggered for review. Furthermore, our analysis
uses a restrictive form of behavioral response as all three CMS CoP triggers must be met
before we estimate its impact on waiting times. Presumably once a transplant center does not

meet any of the three triggers they may alter their behavior to improve their outcomes. Our
current model does not capture the marginal effect that each of the triggers has on waiting
times, nor does it provide an ordinal rank for the impact that the three triggers have on waiting
times. Our empirical estimates only address the responses of those who did not meet the CMS
CoP and treats those centers that are altering behavior to prevent a trigger the same as those
who are well above meeting the triggers. Therefore, we are estimating an average effect for
these two types of centers that currently meet the CMS CoP.
Longer waiting times presumably imply an increase in dialysis time but we do not know
whether this results in a better donor organ for that recipient in the future. This could result in an
increase in graft and patient survival rates, or an increase in adverse outcomes (i.e., delisting of
patients due to deteriorated health, deaths on waiting list). Either of these two outcomes may
result and further research is required to definitively answer this question. In addition, the timing
of non CMS CoP compliance during the study observation period is a potential limitation in that
noncompliance at the end of the observation period may have a very different effect on behavior
during the study period as compared to noncompliance at the beginning that could have a longlasting effect throughout the study.
CONCLUSION:
SRTR reports and CMS review are intended to improve performance and outcomes
throughout the transplant community. When a transplant center does not meet one of the CMS
CoP for 1-year patient survival or graft survival waiting times are longer. While quality of care for
our patients is the most important priority, the transplant community should focus on the balance
between quality outcomes and the full range of outcomes that may affect patients who have not
been transplanted. Longer times on the waitlist may mean more deaths and sicker patients
coming to transplant as a result of remaining on dialysis or better quality care for our patients.
As the United States transplant community debates a proposed new kidney allocation system
and works to develop better risk adjusted models, perhaps including behavioral factors will

guide us to the balance between quality outcomes and utilization. From these data it is clear
that further research is needed on the individual decision-making of transplant physicians to
obtain a better understanding of whether regulatory oversight tips the balance too far in either
direction.
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Figure 1: Fraction of transplant centers (N=188) that do not meet different performance
standards: (1) Observed minus expected exceeds 3 (solid blue line), (2) ratio of observed to
expected exceeds 1.5 (dashed green line with circles), and (3) both (1) and (2) hold and the
differences are statistically significant at the 0.10 level as reported in the SRTR reports (orange
dashed line).

Figure 2: Cumulative Distribution Function (CDF) of waiting time until transplant for patients
whose centers met the CMS CoP the entire time of their waiting period (blue line) and did not
meet the CMS CoP at least once during their waiting time period (blue dashed line) broken
down by graft and patient type. Plot also contains the CDF for the current wait time status of
patients who have not received a transplant broken down by those centers who have met CMS
CoP the entire wait time (orange line) and those that have not met the CMS CoP at least once
during their wait time (orange dashed line).
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Figure 3: Estimated probability of having received a transplant conditional on a patients current
waiting time for those patients whose center met the CMS CoP the entire time of their waiting
period (blue line) and did not meet the CMS CoP at least once during their waiting time period
(blue dashed line) broken down by graft and patient type. Estimated probabilities were obtained
using the duration model results illustrated in Table 2.
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Table 1: Descriptive Statistics: Patient-specific factors broken down by CMS CoP and those
registered patients who have received a transplant and are waiting for a transplant. Averages
illustrated with standard deviations in parentheses. Total number of observations, transplanted
(28,839) and not transplanted (79,725), is 108,564 observations.

1-year graft: Total
Patients
Wait Time (dys)
Previous TX
BMI
Hypertension
Age
Initial PRA>=80
Maximum PRA>=80
Diabetes
Number of Obs.
1-year graft: Dec.
Donor
Wait Time (dys)
Previous TX
BMI
Hypertension
Age
Initial PRA>=80
Maximum PRA>=80
Diabetes
Number of Obs.
1-year patient:
Total Patients
Wait Time (dys)
Previous TX
BMI
Hypertension
Age
Initial PRA>=80
Maximum PRA>=80
Diabetes
Number of Obs.
1-year patient: Dec.
Donor
Wait Time (dys)
Previous TX
BMI
Hypertension
Age
Initial PRA>=80
Maximum PRA>=80
Diabetes
Number of Obs.

Transplanted:
No CMS

Transplanted:
Yes CMS

Waiting:
No CMS

Waiting:
Yes CMS

962.726 (791)
0.060 (0.24)
28.220 (5.71)
0.319 (0.47)
50.246 (12.87)
0.024 (0.15)
0.105 (0.31)
0.376 (0.48)
26,141

1,006.718 (779)
0.060 (0.24)
27.977 (5.67)
0.334 (0.47)
49.085 (13.01)
0.020 (0.14)
0.099 (0.30)
0.350 (0.48)
2,698

804.596 (809)
0.024 (0.15)
28.541 (5.82)
0.212 (0.41)
50.319 (12.95)
0.023 (0.15)
0.073 (0.26)
0.404 (0.49)
72,578

990.573 (847)
0.020 (0.14)
28.285 (5.89)
0.242 (0.43)
49.473 (13.12)
0.015 (0.12)
0.075 (0.26)
0.371 (0.48)
7,147

954.366 (787)
0.060 (0.24)
28.203 (5.70)
0.313 (0.46)
50.244 (12.87)
0.025 (0.15)
0.105 (0.31)
0.378 (0.48)
26,088

1,085.146 (812)
0.062 (0.24)
28.150 (5.78)
0.389 (0.49)
49.125 (12.99)
0.017 (0.13)
0.101 (0.30)
0.340 (0.47)
2,751

796.113 (802)
0.024 (0.15)
28.533 (5.81)
0.208 (0.41)
50.322 (12.95)
0.023 (0.15)
0.072 (0.26)
0.404 (0.49)
72,606

1,077.825 (894)
0.024 (0.15)
28.370 (6.02)
0.284 (0.445)
49.441 (13.10)
0.015 (0.12)
0.078 (0.27)
0.371 (0.48)
7,119

943.479 (777)
0.061 (0.24)
28.194 (5.69)
0.315 (0.46)
50.278 (12.90)
0.024 (0.15)
0.104 (0.31)
0.377 (0.48)
25,586

1,150.591 (863)
0.055 (0.13)
28.226 (5.83)
0.359 (0.48)
49.024 (12.76)
0.022 (0.15)
0.105 (0.31)
0.350 (0.48)
3,253

791.095 (792)
0.023 (0.15)
28.508 (5.81)
0.207 (0.41)
50.387 (12.97)
0.022 (0.15)
0.070 (0.26)
0.406 (0.49)
70,874

1,062.874 (938)
0.025 (0.16)
28.600 (6.00)
0.277 (0.45)
49.092 (12.89)
0.025 (0.16)
0.093 (0.29)
0.365 (0.48)
8,851

955.608 (786)
0.061 (0.24)
28.202 (5.69)
0.319 (0.47)
50.204 (12.88)
0.024 (0.15)
0.105 (0.31)
0.375 (0.48)
26,337

1,085.085 (821)
0.050 (0.22)
28.156 (5.82)
0.335 (0.47)
49.432 (12.90)
0.023 (0.15)
0.096 (0.30)
0.360 (0.48)
2,502

805.054 (805)
0.024 (0.15)
28.506 (5.81)
0.211 (0.41)
50.305 (12.98)
0.021 (0.14)
0.072 (0.26)
0.403 (0.49)
72,228

977.473 (882)
0.015 (0.12)
28.636 (6.04)
0.248 (0.43)
49.652 (12.88)
0.028 (0.16)
0.083 (0.28)
0.385 (0.49)
7,497

Table 2: Cox proportional hazard model parameter estimates. Parameter estimates are the
hazard ratios for the binary indicator variable of whether or not a transplant center did not meet
the CMS CoP during a registered patient’s waiting time. All regression models were estimated
seperately. Additional control variables in the model are: transplant center fixed effects and
patient specific factors (i.e., gender, ethnicity, medical insurance, working status, functional
status at listing, diabetes, vascular disease, angina, hypertension, BMI, age and pra). Statistical
significance: *significant at the 90% level; **significant at the 95% level. LR (chi-squared) tests
for each of the Cox-proportional hazard models indicated next to the parameter estimates.
CMS CoP

Hazard Ratio
(Initial PRA)

1-year graft survival:
total transplants
1-year graft survival:
deceased-donors
1-year patient survival:
total transplants
1-year patient survival:
deceased-donors

0.35835**
(0.015)
0.34225**
(0.012)
0.37995**
(0.013)
0.43433**
(0.016)

LR ( c 2 ) test
(p-value)
23,136.47
(0.00)
23,409.32
(0.00)
23,266.76
(0.00)
23,001.83
(0.00)

Hazard Ratio
(Max. PRA)
0.35602**
(0.014)
0.34181**
(0.012)
0.37818**
(0.013)
0.43109**
(0.16)

LR ( c 2 ) test
(p-value)
23,101.45
(0.00)
23,369.87
(0.00)
23,231.27
(0.00)
22,968.26
(0.00)

Table 3: Cox proportional hazard model parameter estimates. Parameter estimates are the
hazard ratios for the binary indicator variable of whether or not a transplant center did not meet
the CMS CoP during a registered patient’s waiting time interacted with patient specific risk
factors. All regression models were estimated seperately. Additional control variables in the
model are: transplant center fixed effects and patient specific factors (i.e., gender, ethnicity,
medical insurance, working status, functional status at listing, diabetes, vascular disease,
angina, hypertension, BMI, age and pra). Statistical significance: *significant at the 90% level;
**significant at the 95% level.

Variable
Functional Status
1
Functional Status
2
Functional Status
3
Diabetes
Angina
CAD
PVD
Hypertension
Previous TX
BMI
Age
PRA>=80
(Initial PRA)
PRA>=80
(Maximum PRA)
LR (

c 2 ) test –

(p-value)

1-year graft survival
Total
Total
Trans.
Trans.
1.0302
1.0291
(0.06)
(0.06)
0.8575**
0.8595**
(0.06)
(0.06)
0.6958
0.6860
(0.19)
(0.19)
1.0870*
1.0836*
(0.05)
(0.05)
0.8788
0.9022
(0.13)
(0.14)
1.0845
1.1589
(0.22)
(0.23)
1.1302
1.1312
(0.12)
(0.12)
1.0780*
1.0793*
(0.05)
(0.05)
1.1979**
1.2402**
(0.11)
(0.12)
0.9772**
0.9774**
(0.00)
(0.00)
0.9931**
0.9930**
(0.00)
(0.00)
1.0450
---(0.15)
---0.8768*
(0.06)
23,110.26
23,077.11
(0.00)
(0.00)

1-year graft survival
Dec. Donor Dec. Donor
0.9856
(0.05)
0.7814**
(0.06)
0.6647
(0.20)
1.0742
(0.05)
0.9556
(0.13)
1.0497
(0.20)
1.2478**
(0.13)
1.1783**
(0.05)
1.0921
(0.09)
0.9767**
(0.00)
0.9923**
(0.00)
0.8729
(0.13)
---23,373.49
(0.00)

0.9852
(0.05)
0.7812**
(0.06)
0.6579
(0.25)
1.0669
(0.05)
0.9751
(0.13)
1.1026
(0.21)
1.2609**
(0.13)
1.1766**
(0.05)
1.1292
(0.10)
0.9772**
(0.00)
0.9923**
(0.00)
---0.8541**
(0.06)
23,338.43
(0.00)

1-year patient survival
Total
Total
Trans.
Trans.
0.9547
0.9536
(0.05)
(0.05)
0.7778**
0.7843**
(0.05)
(0.05)
0.6438
0.6336
(0.19)
(0.18)
1.1204**
1.1191**
(0.05)
(0.05)
1.0529
1.0280
(0.12)
(0.12)
1.0038
0.9886
(0.17)
(0.17)
1.1389
1.1323
(0.11)
(0.11)
1.0657
1.0784*
(0.04)
(0.05)
0.9313
1.0346
(0.08)
(0.09)
0.9782**
0.9783**
(0.00)
(0.00)
0.9947**
0.9948**
(0.00)
(0.00)
0.8611
---(0.11)
---0.8106**
(0.05)
23,228.72
23,200.68
(0.00)
(0.00)

1-year patient survival
Dec.
Dec.
Donor
Donor
1.0429
1.0478
(0.06)
(0.06)
0.7946**
0.7962**
(0.06)
(0.06)
0.5834
0.5735
(0.24)
(0.24)
1.1061**
1.0948*
(0.05)
(0.05)
1.0519
1.0154
(0.15)
(0.15)
0.8880
0.8883
(0.22)
(0.22)
1.0926
1.0995
(0.12)
(0.12)
0.9799
0.9745
(0.05)
(0.04)
1.1277
1.2588**
(0.11)
(0.13)
0.9778**
0.9784**
(0.00)
(0.00)
0.9966**
0.9965**
(0.00)
(0.00)
1.0670
---(0.15)
---0.8076**
(0.06)
23,000.00
22,973.86
(0.00)
(0.00)

